Search

Yazeed Sawalha, David A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USACorrespondence: Yazeed SawalhaDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital, A350B Starling-Loving Hall, 320 W. 10th Ave., Columbus, OH 43210, USATel +1 614-293-0837Fax +1 614-293-7526Email Yazeed.Sawalha@osumc.eduAbstract: Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized by an aggressive clinical course in the majority of patients. Despite recent improvements in outcomes, MCL remains incurable and a major therapeutic challenge. BTK inhibitors are the preferred treatment option for patients with relapsed/refractory MCL, including those unfit for chemotherapy or those with chemoresistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85– 87% with complete responses in 30– 77% of patients. Compared with ibrutinib, zanubrutinib is more selective for BTK and has less off-target inhibition, which is thought to limit certain toxicities although direct comparative data are still lacking. This review article summarizes data from clinical trials of currently FDA-approved BTK inhibitors in MCL with a focus on zanubrutinib.Keywords: BTK, zanubrutinib, ibrutinib, acalabrutinib

Yazeed Sawalha, Kami Maddocks Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USACorrespondence: Yazeed SawalhaDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital, A350B Starling-Loving Hall, 320 W. 10th Ave., Columbus, OH 43210, USATel +1 614-293-0837Fax +1 614-293-7526Email Yazeed.sawalha@osumc.eduAbstract: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.Methods: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.Keywords: CD79, antibody-drug conjugate, polatuzumab, clinical trials, novel &nbsp

Sawalha Y, Bond DA, Alinari L. Onco Targets Ther.2020;13:6573—6581. The authors have advised that there is an error in Table 2on page 6579. The values “37% (0%)” in the first row forthe Ibrutinib column should read “10% (0%)”. The authors apologize for this error and advise it does notaffect the conclusions of the paper. Read the original article